Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elicera Therapeutics ABFRA:8E8 +2.70%24 EV-to-EBITDA is -7.25 as of Sep. 07, 2026. GuruFocus rates FRA:8E8 with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 399 Biotechnology companies, Elicera Therapeutics AB ranks worse than 250626.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Elicera Therapeutics AB's enterprise value is €12.09 Mil.
Elicera Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.67 Mil. Therefore, Elicera Therapeutics AB's EV-to-EBITDA for today is -7.25.
The historical rank and industry rank for Elicera Therapeutics AB's EV-to-EBITDA or its related term are showing as below:
FRA:8E8'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.4 Med: 0 Max: 0
Current: -7.4
FRA:8E8's EV-to-EBITDA is ranked worse than 100% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs FRA:8E8: -7.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Elicera Therapeutics AB (FRA:8E8) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Elicera Therapeutics AB's PE Ratio (TTM) for today is calculated as:
Elicera Therapeutics AB's share price for today is €0.228.
Elicera Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.032.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8E8 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Elicera Therapeutics AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicera Therapeutics AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Elicera Therapeutics AB's EV-to-EBITDA falls into.
Elicera Therapeutics AB's current Enterprise Value is €12.09 Mil.
Elicera Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicera Therapeutics AB (FRA:8E8) has a EV-to-EBITDA of -7.25 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elicera Therapeutics AB. According to the industry distribution chart, Elicera Therapeutics AB ranks #999999 out of 399 companies in the Biotechnology industry.
Is Elicera Therapeutics AB's EV-to-EBITDA too high?
Elicera Therapeutics AB's current EV-to-EBITDA is -7.25. Based on the distribution chart, Elicera Therapeutics AB ranks #999999 out of 399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Elicera Therapeutics AB has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Elicera Therapeutics AB ranks #999999 out of 399 companies for EV-to-EBITDA. This places Elicera Therapeutics AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elicera Therapeutics AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elicera Therapeutics AB's current EV-to-EBITDA is -7.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (FRA:8E8) has a current EV-to-EBITDA of -7.25. The current EV-to-EBITDA is -7.25. Elicera Therapeutics AB's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Elicera Therapeutics AB (FRA:8E8), the current EV-to-EBITDA is -7.25 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
24GF Score
Get the complete analysis for FRA:8E8
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8E8 has been successfully added to your 
